Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) pre-open: what’s a preferred narrative?

January 13, 2021 7:56am

A definition of expectation as coronavirus and impeachment efforts temper markets

Pre-open indication: 6 SELLs and 5 BUYs

What I provide is a trusted source of share pricing intelligence that ensures that investors are kept apprised of “our” universe, the RegMed/cell and gene therapy sector and its surrounding markets

Subscription is coming, it’s not conscription but, an offer to join our collective of like-minded investors!

Dow futures are DOWN -0.16% (-49 points), S&P futures are DOWN -0.23% (-9 points) and NASDAQ futures are DOWN -0.15% (19 points)

U.S. stock index futures fluttered in premarket trading Wednesday as the market struggled for direction amid rising rates, political uncertainty and soaring COVID-19 infections and hospitalizations;

European markets mixed with vaccine rollout and COVID-19 lock-downs which have been extended in Germany and the Netherlands;

Asia-Pacific markets were mixed; the Japanese government expand the state of emergency to more areas in a bid to stem a rise in coronavirus infections. Chinese authorities in regions near Beijing are stepping up restrictions on social activity following a rise in new cases.

Henry’omics:

Markets are looking sluggish …

Following Tuesday’s muted session, the major averages remain lower for the week after Monday’s slide. The Nasdaq was down roughly 1% over the last two (2) sessions while the Russell 2000 is up 1.7% so far this week.

Data Docket: the release of consumer prices for December, the Beige Book, the federal budget statement for December, and speeches from Federal Reserve Gov. Lael Brainard, Vice Chair Richard Clarida, St. Louis Fed President James Bullard and Philadelphia Fed President Patrick Harker.

Tuesday’s evening’s recap: RegMed Investors’ (RMi) closing bell: “in which wave are we investing? Learn to pick the right wave, investors, all waves are NOT the same: the bigger, the better” and fine tune the peaks, periods of time and swells” … https://www.regmedinvestors.com/articles/11718

The Nasdaq closed UP +36 points (+0.28%);
The IBB closed up +0.25% and XBI closed up +0.87%;
Sector volume was BALANCED with 8 of the 21-upside having higher than the 3-month average volume with the increased volume of 5 of 13-downside having higher than the 3-month average volume;
The CBOE Volatility Index (VVIX: INDEX) was down -0.75 points or -3.11% at 23.33
Tuesday’s percentage (%) of the 21-upside were +0.04% (FATE) to +12.25% RENE.L() while the 13-downside ranges from -0.77% (MDXG) to -10.18% (MESO);

January:

5 positive and 2 negative closes, so far

Companies in my headlights – It’s your decision; I provide an idea and context:

Maintaining Sell:

Biostage (BSTG) closed up +$ -$0.06 to $1.10 with 3,202 shares traded after Friday’s -$0.04 to $1.16 with 700 shares traded, Thursday’s -$0.01 to $1.20 with 2,600 shares trade, Wednesday’s -$0.06 to $1.21 with 400 shares traded and last Tuesday’s -$0.10 to $1.15 with 11,900 shares traded. Reiterating the questions …

Question#1: WHY does Chinese investor DST Capital and Beijing based Dixintong Technology Group need a regenerative medicine/biotech public, PPP debtor and money losing company in its investment group that resides in the middle of medical and scientific innovation in America?
Question#2: Don’t U.S. public shareholders deserve accountability of WHAT is the mission going forward and WHAT data are they accumulating?

Maintaining SELL into Strength:

Athersys (ATHX) closed up +$0.08 to $2.00 after Monday’s $1.92 and has a negative -$0.06 or -3% and a 52-week change of +43.28%;

bluebird bio (BLUE) closed up +$1.93 to $52.33 after Tuesday’s $50.40 and Monday’s $48.54 with a positive +$0.57 or +1.09% pre-market indication;

Intellia Therapeutics (NTLA) closed down -$5.58 to $72.78 after Friday’s +$0.88 to $78.36, Thursday’s +$10.74, Wednesday’s +$5.73 and last Tuesday’s +$5.10 and has a negative -$0.18 or -0.25% aftermarket indication;

CRISPR therapeutics (CRSP) closed up +$1.46 to $190.34 after Monday’s -$4.94 to $188.88, Friday’s $193.82, Thursday’s $194.43, Wednesday’s $163.85 and last Tuesday’s $160.62 with a positive +$2.66 or +1.40 % aftermarket indication and a 52-week change of +228.56%;

BUY:

Applied Genetic Technologies (AGTC) closed up +$0.04 to $4.60 after Monday’s $4.56 and has a positive +$0.08 or +1.74% aftermarket indication;

BioLife Solutions (BLFS) closed down -$0.34 to $40.11 after Monday’s $40.45 and has a positive +$0.88 or +2.19% aftermarket indication and a 52-week change of +155.53%;

Global Blood therapeutics (GBT) closed up +$0.24 to $46.14 after Monday’s $45.90 and has a negative -$0.07 or -0.15% aftermarket indication having started the month and New Year at $44.26;

Homology Medicine (FIXX) closed up +$0.31 to $12.62 after Monday’s $12.31 and has a positive +$0.19 or +1.43% aftermarket indication;

Pluristem (PSTI) closed down -$0.18 to $8.31 after Monday’s $8.49 and has a positive +$0.07 or +0.84% pre-market indication;

Maintaining SELL:

Mesoblast (MESO) closed down -$1.16 to $10.24 after Monday’s +$2.74 to $11.40 after Friday’s -$0.26 to $8.66 and has a negative -$0.49 or -4.79% pre-market indication on news, another bounce-down;

The BOTTOM LINE: Investors are waiting for fiscal aid “numbers” and timetable but, looking for reasons to BUY stocks.

Real issue, “the U.S. coronavirus situation continues to be bleak — the 7-day averages of new cases and hospitalizations are at records, with 4,056 deaths on Tuesday alone, according to the COVID tracking project.” <MarketWatch>

Earnings season Is about to begin. Investors are considering whether they should ignore and wait for Q2.

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.